Concepedia

Author

Andreas Hüser

Charité - Universitätsmedizin Berlin

Also Known As

A. Hüser, Andreas Huser, Andreas Hüser, Hüser, Andreas

17

Publications

744

Citations

10

H-Index

13

Concepts

All Affiliations

Charité - Universitätsmedizin BerlinNovartis (Switzerland)
AH

About

Andreas Hüser is an author at Charité - Universitätsmedizin Berlin specializing in medicine, virology, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

245

2

Immunology

2

2

157

3

Pathology

1

1

39

4

Pharmacology

1

1

88

5

Immunotherapy

1

1

39

Andreas Hüser

×

9

Publications

696

Citations

9

H-Index

YearCitations

Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity

Thomas Dörner, Maximilian Posch, Yue Li,

Annals of the Rheumatic Diseases

2019

189

Baculovirus-based Vaccination Vectors Allow for Efficient Induction of Immune Responses Against Plasmodium falciparum Circumsporozoite Protein

Robert Strauss, Andreas Hüser, Shaoheng Ni,

Molecular Therapy

2006

129

Incorporation of decay-accelerating factor into the baculovirus envelope generates complement-resistant gene transfer vectors

Andreas Hüser, Michael Rudolph, Christian Hofmann

Nature Biotechnology

2001

118

Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial

Dirk Schürmann, Deanne Jackson Rudd, Saijuan Zhang,

The Lancet HIV

2020

88

Baculovirus vectors: novel mammalian cell gene-delivery vehicles and their applications.

Andreas Hüser, Christian Hofmann

PubMed

2003

66

Protection of Baculovirus-Vectors against Complement-Mediated Inactivation by Recombinant Soluble Complement Receptor Type 1

Christian Hofmann, Andreas Hüser, Wolfgang Lehnert,

Biological Chemistry

1999

39

Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases

Fredrik N. Albach, Frank Wagner, Andreas Hüser,

European Journal of Clinical Pharmacology

2017

33

Antiviral Activity, Safety, and Exposure–Response Relationships of GSK3532795, a Second-Generation Human Immunodeficiency Virus Type 1 Maturation Inhibitor, Administered as Monotherapy or in Combination With Atazanavir With or Without Ritonavir in a Phase 2a Randomized, Dose-Ranging, Controlled Trial (AI468002)

Carey Hwang, Dirk Schürmann, Christian Sobotha,

Clinical Infectious Diseases

2017

23

THU0313 Double-Blind, Randomized Study of VAY736 Single Dose Treatment in Patients with Primary Sjögren's Syndrome (PSS)

Thomas Dörner, Maximilian Posch, Florian Wagner,

Annals of the Rheumatic Diseases

2016

11

Page 1